Company News

Fierce Biotech: Chutes & Ladders
Elicio Therapeutics, developing immunotherapies that leverage its proprietary lymph node targeting technology, has named Annette Matthies, Ph.D., as chief business officer. Matthies played a key role in the initial public offering for Receptos, later picked up by Celgene for $7.2 billion, and also worked at Abbott Laboratories after its $450 million buyout of Facet Biotech, where she served in a post-acquisition integration position. Release » Read more
South Africa’s coronavirus strain upends country’s vaccination plans
LA TIMES: The coronavirus strain fueling a resurgence of COVID-19 in South Africa was not slowed down by a vaccine that officials had been counting on to protect its front-line healthcare workers, prompting the government to shelve plans for an inoculation campaign that would have begun this month. “We have decided to put a temporary […] » Read more
Appointments and advancements for Feb. 2, 2021
BIOWORLD: New hires and promotions in the biopharma industry » Read more
Next-gen Covid-19 vaccines: Elicio and its lymph node targeting approach
PHARMACEUTICAL TECHNOLOGY One next-generation Covid-19 vaccine that is about to enter clinical studies is Elicio’s ELI-005. This lymph node-targeting vaccine is composed of an adjuvant developed using the company’s Amphiphile technology and the SARS-CoV-2 virus’s spike protein RBD. Elicio head of research and development Christopher Haqq explains the differentiated mechanism of the action of this […] » Read more
ENDPOINTS: Christopher Haqq joins Elicio to hunt father’s RAS cancer
Christopher Haqq is now joining Elicio as its new R&D chief, overseeing the development of, among other things, their RAS-targeting immunotherapy. RAS mutations, which are now after 40 years of research becoming a prime target for experimental therapies, are present in about 30% of cancers, including 45% of colon cancers and nearly all pancreatic cancers. » Read more
ENDPOINTS: Elicio Therapeutics — focused on amphiphile immunotherapies — has closed its Series B with $33 million
Darrell Irvine co-founded Elicio Therapeutics — focused on amphiphile immunotherapies — has closed its Series B with $33 million. The company says that the financing will advance Elicio’s pipeline, including its amphiphile mKRAS vaccine, ELI-002 — which targets seven KRAS mutations that drive 99% of all KRAS-driven cancers. Investors for the round included Clal Biotechnology […] » Read more
BioCentury: Elicio to Advance Pancreatic, HPV Vaccines, CAR T Booster With $33M B Round
Six months after raising a $30 million series A round, Elicio has added $33 million via its B round to begin Phase I/II testing of its KRAS-driven cancer vaccine ELI-002 and advance its other immunotherapies. » Read more
BioCentury: Elicio vaccine targets oncogenic KRAS mutations
Elicio Therapeutics (Cambridge, Mass.) showed its ELI-002 vaccine generated immune responses against all common KRAS mutations, resulting in cytolytic activity against cells expressing the mutations. » Read more
Science: Boosting engineered T cells
After decades of work, researchers have finally begun to see broadly reproducible success of engineered T cells in the treatment of cancer. » Read more
ENDPOINTS: Su­per­charg­ing CAR-T with can­cer vac­cine, MIT team spot­lights some new tech un­der­pin­ning Dar­rell Irvine’s start­up
What if just amplifying CAR-T cells can do the job? Darrell Irvine and his team at MIT have some intriguing mouse data for one such tech. » Read more
Fierce Biotech: Boosting CAR-T to treat solid tumors with a vaccine
Using a vaccine that super-charges CAR-Ts at the lymph nodes, an MIT team found that they could eliminate solid tumors in 60% of mice. After that, the animals also cleared re-injected tumor cells. The findings were published in Science. » Read more
Xconomy: Bio Roundup: Amyloid Angst, NASH News, Brammer Bagged & More
Xconomy National— A week after the failure of Biogen’s Alzheimer’s drug aducanumab, the ripple effects are still being felt—and not just by Biogen, which lost billions of dollars in market value in a flash. We’ll kick off this week’s roundup with the aducanumab reaction, which includes plenty of thoughts about the future of the so-called […] » Read more
ENDPOINTS: Three biotechs raise $100M+ in funding for gene therapies, cancer vaccines and more
– Another day, another gene therapy developer. Prevail Therapeutics, which leapt out of stealth mode in 2017 and raised $75 million in a Series A last year for its disease-modifying approach to neurode generative diseases, has secured another $5o million in the bank. The New York-based company is run by Columbia University’s Asa Abeliovich, who […] » Read more
FierceBiotech: Elicio Therapeutics aims to sneak cancer vaccines into the lymph nodes, with $30M to launch
by Conor Hale – By targeting the body’s lymph nodes with anti-cancer vaccines, new immunotherapy developer Elicio Therapeutics aims to focus on ground zero of the body’s immune system. And to do it, the startup is getting underway with $30 million in funds, a new CEO and tech from the Massachusetts Institute of Technology. Elicio […] » Read more
BioCentury: Elicio raises $30m to target cancer vaccines to the lymph nodes
by Mary Romeo, Staff Writer – Elicio launched Wednesday with $30 million in funding and an immunotherapy strategy aimed at getting cancer vaccines into the lymph nodes, a location that orchestrates immune responses but has been hard to target directly. Elicio Therapeutics (Cambridge, Mass.) has exclusively licensed the Amphiphile platform from Darrell Irvine at the […] » Read more